Literature DB >> 1849708

In vitro activity of azithromycin against clinical isolates of Legionella species.

P H Edelstein1, M A Edelstein.   

Abstract

The activities of azithromycin, erythromycin, and ciprofloxacin against 21 Legionella isolates were measured by an agar dilution method and in macrophages. The MICs for 90% of strains tested were 2.0, 1.0, and 0.5 micrograms/ml for azithromycin, erythromycin, and ciprofloxacin, respectively. Azithromycin and ciprofloxacin were both bactericidal in the macrophage system, but erythromycin was bacteriostatic.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1849708      PMCID： PMC244963          DOI： 10.1128/AAC.35.1.180

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

2.  WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

3.  Pharmacokinetics of azithromycin in rats and dogs.

Authors:  R M Shepard; F C Falkner
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol.

Authors:  R B Fitzgeorge; A S Featherstone; A Baskerville
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

Authors:  F G Araujo; D R Guptill; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

7.  Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex.

Authors:  L E Bermudez; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

8.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191
  8 in total
  19 in total

1.  Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.

Authors:  D M Johnson; M E Erwin; M S Barrett; B B Gooding; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.

Authors:  Paul H Edelstein; Baofeng Hu; Martha A C Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.

Authors:  F Higa; N Kusano; M Tateyama; T Shinzato; N Arakaki; K Kawakami; A Saito
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

6.  In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; F Higa; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 7.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

9.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 10.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.